Physician profile
Adam M Parsons
NPI 1417203894
$2,186.93
in general payments reported to CMS, 2019-2025
26 companies · $225 in 2025
The $225 reported for 2025 was more than what a typical Sports Medicine (Internal Medicine) provider received nationally (typical 2025 total: $99.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $495 · 2020: $357 · 2021: $747 · 2022: $243 · 2024: $120 · 2025: $225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $344.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $380.70 | 2019-2025 | Xifaxan |
| Novo Nordisk INC | $246.27 | 2020-2022 | |
| Mdd US Operations, LLC | $228.79 | 2019-2020 | |
| Amgen INC. | $221.09 | 2020-2022 | |
| Hologic Sales and Service, LLC | $150.00 | 2025 | Aptima |
| Abbvie INC. | $135.64 | 2021-2024 | |
| Medtronic, INC. | $129.23 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $93.24 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $67.33 | 2020-2022 | |
| Astrazeneca Pharmaceuticals Lp | $61.87 | 2021-2022 | |
| Lilly USA, LLC | $53.62 | 2021-2022 | |
| Si-Bone, INC. | $52.24 | 2019-2020 | |
| Stryker Corporation | $49.91 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.52 | 2021-2022 | |
| Pfizer INC. | $42.32 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $39.43 | 2021 | |
| Exact Sciences Corporation | $34.03 | 2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $24.29 | 2021 | |
| Shionogi INC | $19.43 | 2019 | |
| Almatica Pharma LLC | $17.75 | 2021 | |
| Biodelivery Sciences International, INC. | $17.52 | 2020 | |
| Xeris Pharmaceuticals, INC. | $16.98 | 2022 | |
| Mylan Specialty L.P. | $16.66 | 2020 | |
| Aytu Biopharma, INC. | $14.92 | 2020 | |
| Pernix Therapeutics Holdings, INC. | $14.17 | 2019 | |
| Antares Pharma, INC. | $13.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Parsons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.